Education
About Us
Working with TipRanks
Follow Us
LIDDS AB (SE:LIDDS)
:LIDDS
LIDDS Stock Chart & Stats
kr0.04
kr0.00(0.00%)
At close: 4:00 PM EST
kr0.04
kr0.00(0.00%)
Day’s Range― - ―
52-Week Range<kr0.01 - kr0.14
Previous CloseN/A
Volume21.10K
Average Volume (3M)48.19K
Market Cap
kr3.36M
Enterprise Valuekr1.62M
Total Cash (Recent Filing)kr1.73M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Feb 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding136,463,330
10 Day Avg. Volume51,372
30 Day Avg. Volume48,191
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.24
Price to Sales (P/S)432.85
P/FCF Ratio-2.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Drug‑delivery PlatformOwning NanoZolid® offers a structural competitive advantage: a platform for sustained local delivery that can improve efficacy and reduce systemic toxicity. This platform approach increases partnerability and potential licensing across indications, supporting durable value creation if clinical progress continues.
Zero Financial LeverageA debt‑free balance sheet materially lowers bankruptcy and interest‑service risk, giving management flexibility to pursue partnerships, R&D or milestone financing. Over months, zero leverage preserves cash flow for operations and reduces fixed obligations versus leveraged peers.
Declining Cash Burn TrendA sustained reduction in operating and free‑cash‑flow burn indicates improved cost control and operational discipline. Reduced burn lengthens runway, lowers near‑term financing pressure, and improves the odds management can reach clinical inflection points or licensing discussions without immediate dilutive raises.
Bears Say
Minimal Commercial RevenueNear‑zero revenues mean the business is not yet product‑commercial and lacks sustainable internal cash generation. Over the medium term this forces reliance on external financing or licensing for R&D and operations, increasing dilution and execution risk until commercial or partner revenue materializes.
Material Erosion Of EquityA sharply reduced equity cushion weakens the company’s ability to absorb continued losses and increases the probability of dilutive capital raises. Over months this constrains strategic optionality, heightens investor sensitivity to funding events, and may complicate partnering or credit discussions.
Persistent Negative Operating Cash FlowSustained negative operating and free cash flow means the company cannot self‑fund development activities. Structurally, this creates ongoing dependence on external financing, which can delay trials, limit investments, and increase execution risk if capital markets or partner options become constrained.
LIDDS FAQ
What was LIDDS AB’s price range in the past 12 months?
LIDDS AB lowest stock price was <kr0.01 and its highest was kr0.14 in the past 12 months.
What is LIDDS AB’s market cap?
LIDDS AB’s market cap is kr3.36M.
When is LIDDS AB’s upcoming earnings report date?
LIDDS AB’s upcoming earnings report date is Feb 19, 2026 which is tomorrow.
How were LIDDS AB’s earnings last quarter?
LIDDS AB released its earnings results on Nov 20, 2025. The company reported -kr0.006 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.006.
Is LIDDS AB overvalued?
According to Wall Street analysts LIDDS AB’s price is currently Overvalued.
Does LIDDS AB pay dividends?
LIDDS AB does not currently pay dividends.
What is LIDDS AB’s EPS estimate?
LIDDS AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does LIDDS AB have?
LIDDS AB has 136,463,330 shares outstanding.
What happened to LIDDS AB’s price movement after its last earnings report?
LIDDS AB reported an EPS of -kr0.006 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of LIDDS AB?
Currently, no hedge funds are holding shares in SE:LIDDS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
LIDDS AB
LIDDS AB (publ), a pharmaceutical company, develops and sells pharmaceutical products for cancer and other diseases in Sweden. It is developing various drugs, such as NZ-2HOF to treat prostate cancer; NZ-DTX to treat breast, prostate, head, neck, stomach, and lung cancer; NZ-DOX for the treatment of solid tumors; NZ-IO, an immunotherapy; NZ-STING for the treatment of immuno-oncology; and NZ-TLR9 for enhancing cancer immunotherapies. LIDDS AB (publ) has a collaboration agreement with PharmIdea SIA to focus on anti-cancer drugs and sterile formulations. The company is based in Uppsala, Sweden.